Alterity Therapeutics Limited (ATHE)
Develops experimental drugs to treat Parkinson's disease and other neurodegenerative brain disorders
$4.57-0.02%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago-8.9%
The outlook
Analysts are strongly bullish on ATHE, with an average price target roughly 177% above the current price. The stock sits mid-range in its 52-week band and shows mixed momentum against its moving averages. Overall sentiment leans bullish based on current analyst coverage.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 3 analysts
Price trendMixed vs its moving averages
52-week range59% of the way from its 52-week low to high
Price targetAvg target +177% vs current price
Analyst price target
~12-month · 3 analysts$12.67average target+177.5% vs now
Now $4.57
Low $10.00High $16.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$82.7M
52-wk high
$5.89
52-wk low
$2.66
50-day avg
$4.66
200-day avg
$3.96
Trailing P/E
—